Compare PLX & TCGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLX | TCGX |
|---|---|---|
| Founded | 1993 | 2026 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 159.4M |
| IPO Year | 1996 | 2026 |
| Metric | PLX | TCGX |
|---|---|---|
| Price | $2.64 | $12.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 801.0K | 9.0K |
| Earning Date | 08-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.65 | $11.62 |
| 52 Week High | $3.19 | $18.91 |
| Indicator | PLX | TCGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 47.02 |
| Support Level | $2.59 | $12.42 |
| Resistance Level | $2.75 | $15.00 |
| Average True Range (ATR) | 0.10 | 0.77 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 20.00 | 19.71 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
TCGX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.